VARIBAR PUDDING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VARIBAR PUDDING (VARIBAR PUDDING).
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
| Metabolism | Barium sulfate is not metabolized. It is eliminated unchanged in the feces. No hepatic or renal metabolism occurs due to lack of systemic absorption. |
| Excretion | Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate. |
| Half-life | Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage. |
| Protein binding | Not applicable; no systemic absorption, thus no protein binding. |
| Volume of Distribution | Not applicable; no systemic absorption, thus Vd is undefined. |
| Bioavailability | Oral: 0% (barium sulfate is not absorbed; it remains within the GI lumen). |
| Onset of Action | Oral administration: immediate coating of esophageal and gastric mucosa upon ingestion; visualization begins within seconds. |
| Duration of Action | Oral: effects last until the contrast agent passes through the GI tract (approximately 30–60 minutes for upper GI series; 6–24 hours for complete transit). |
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment needed; not systemically absorbed. |
| Liver impairment | No dose adjustment needed; not systemically absorbed. |
| Pediatric use | Neonates: 5-10 mL/kg orally once; Infants/Children: 30-60 mL orally once for upper GI, 60-90 mL for small bowel. Maximum total dose 240 mL. |
| Geriatric use | No specific dose adjustment; use lowest effective volume due to aspiration risk and constipation propensity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VARIBAR PUDDING (VARIBAR PUDDING).
| Breastfeeding | Not absorbed systemically; no risk to breastfeeding infant. M/P ratio not applicable. |
| Teratogenic Risk | Not absorbed systemically; no teratogenic risk in any trimester. |
| Fetal Monitoring | None required due to lack of systemic absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known or suspected gastrointestinal perforation","Known or suspected gastrointestinal obstruction","Tracheoesophageal fistula","Severe dysphagia or aspiration risk (relative, use with caution)","Previous hypersensitivity reaction to barium sulfate preparations"]
| Precautions | ["Risk of aspiration: can cause chemical pneumonitis if aspirated into lungs; use with caution in patients with swallowing difficulties or impaired gag reflex.","Risk of bowel obstruction or perforation: contraindicated in patients with known or suspected bowel obstruction, perforation, or fistula unless specifically indicated.","Hypersensitivity reactions: rare but possible; have resuscitation equipment available.","Constipation: can cause impaction, especially in patients with slow transit or dehydration; ensure adequate hydration post-procedure.","Suspected GI perforation: avoid use as extravasation can cause peritonitis and granuloma formation."] |
Loading safety data…
| Fertility Effects |
| No known effect on fertility. |